Cargando…

In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents

The emergence of antibiotic resistant bacterial pathogens is increasing at an unprecedented pace, calling for the development of new therapeutic options. Small molecules interfering with virulence processes rather than growth hold promise as an alternative to conventional antibiotics. Anti-virulence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mellini, Marta, Di Muzio, Elena, D’Angelo, Francesca, Baldelli, Valerio, Ferrillo, Serena, Visca, Paolo, Leoni, Livia, Polticelli, Fabio, Rampioni, Giordano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796623/ https://www.ncbi.nlm.nih.gov/pubmed/31649658 http://dx.doi.org/10.3389/fmicb.2019.02355

Ejemplares similares

Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
por: Baldelli, Valerio, et al.
Publicado: (2020)

PqsE Expands and Differentially Modulates the RhlR Quorum Sensing Regulon in Pseudomonas aeruginosa
por: Letizia, Morgana, et al.
Publicado: (2022)

Alkyl-quinolone-dependent quorum sensing controls prophage-mediated autolysis in Pseudomonas aeruginosa colony biofilms
por: Giallonardi, Giulia, et al.
Publicado: (2023)

A New Transcriptional Repressor of the Pseudomonas aeruginosa Quorum Sensing Receptor Gene lasR
por: Longo, Francesca, et al.
Publicado: (2013)

The Pseudomonas putida Lon protease is involved in N-acyl homoserine lactone quorum sensing regulation
por: Bertani, Iris, et al.
Publicado: (2007)

In vitro Activity of Antivirulence Drugs Targeting the las or pqs Quorum Sensing Against Cystic Fibrosis Pseudomonas aeruginosa Isolates
por: Collalto, Diletta, et al.
Publicado: (2022)

Unravelling the Genome-Wide Contributions of Specific 2-Alkyl-4-Quinolones and PqsE to Quorum Sensing in Pseudomonas aeruginosa
por: Rampioni, Giordano, et al.
Publicado: (2016)

Affecting Pseudomonas aeruginosa Phenotypic Plasticity by Quorum Sensing Dysregulation Hampers Pathogenicity in Murine Chronic Lung Infection
por: Bondí, Roslen, et al.
Publicado: (2014)

Effect of efflux pump inhibition on Pseudomonas aeruginosa transcriptome and virulence
por: Rampioni, Giordano, et al.
Publicado: (2017)

Gene-Expressing Liposomes as Synthetic Cells for Molecular Communication Studies
por: Rampioni, Giordano, et al.
Publicado: (2019)

Synergistic Activity of Colistin in Combination with Clofoctol against Colistin Resistant Gram-Negative Pathogens
por: Collalto, Diletta, et al.
Publicado: (2023)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
por: Ramakrishnan, Gayatri, et al.
Publicado: (2017)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Differential Regulation of the Phenazine Biosynthetic Operons by Quorum Sensing in Pseudomonas aeruginosa PAO1-N
por: Higgins, Steven, et al.
Publicado: (2018)

The Pseudomonas aeruginosa DksA1 protein is involved in H(2)O(2) tolerance and within-macrophages survival and can be replaced by DksA2
por: Fortuna, Alessandra, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Effect of a Defective Clamp Loader Complex of DNA Polymerase III on Growth and SOS Response in Pseudomonas aeruginosa
por: Spinnato, Maria Concetta, et al.
Publicado: (2022)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs
por: Sahoo, Ajaya Kumar, et al.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

The interplay of StyR and IHF regulates substrate-dependent induction and carbon catabolite repression of styrene catabolism genes in Pseudomonas fluorescens ST
por: Rampioni, Giordano, et al.
Publicado: (2008)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
por: Mee-udorn, Pitchayathida, et al.
Publicado: (2023)

In Silico Analysis of the Quorum Sensing Metagenome in Environmental Biofilm Samples
por: Barriuso, Jorge, et al.
Publicado: (2018)

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
por: Li, Mei, et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)

In Silico Drug Repurposing Approach: Investigation of Mycobacterium tuberculosis FadD32 Targeted by FDA-Approved Drugs
por: Ngidi, Nolwazi Thobeka Portia, et al.
Publicado: (2022)

Editorial note: repurposing FDA approved drugs as FXR agonists: a structure based in silico pharmacological study
Publicado: (2022)

In silico structural analysis of quorum sensing genes inVibrio fischeri
por: Zaghlool, Mohammed, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o3sob9q71nfv5r48l58abo6aei